nan
Cardboard Cat Scratcher Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The lutetium-177 supply market size has experienced rapid expansion in recent years. It is forecast to increase from $1.4 billion in 2025 to $1.63 billion in 2026, at a compound annual growth rate (CAGR) of 15.7%. The growth observed in prior periods can be attributed to an escalating prevalence of cancer indications that require targeted radionuclide therapy, a greater clinical adoption of radiopharmaceutical treatments, the worldwide expansion of nuclear medicine infrastructure, augmented investments in facilities for medical isotope production, and a rise in regulatory clearances for lutetium-177 based therapies.
The lutetium-177 supply market is projected to experience substantial expansion over the upcoming years. This market is set to reach $2.94 billion by 2030, achieving a compound annual growth rate (CAGR) of 15.9%. This anticipated growth is driven by several factors, including the surging demand for precision oncology treatments, an expanding capacity for commercial radiopharmaceutical manufacturing, increased investments in advanced isotope production technologies, the ongoing development of new lutetium-177 therapeutic applications, and the development of regional isotope supply networks. Key trends during this period encompass the continued expansion of reactor-based isotope production capabilities, a heightened emphasis on high-purity lutetium-177 supply chains, increased capital allocation for radiopharmaceutical logistics infrastructure, wider adoption of non-carrier added lutetium-177 production techniques, and a strengthened focus on regulatory-compliant isotope transportation systems.
Download A Free Sample Report For Comprehensive Market Insights:
#Lutetium-177 Supply Market Growth Drivers And Industry Catalysts
The expanding occurrence of cancer is anticipated to stimulate the progression of the lutetium-177 supply market moving forward. Cancer refers to a collection of diseases where abnormal cells multiply uncontrollably, infiltrate tissues, and possess the ability to spread to other parts of the body. The incidence of cancer is climbing due to an aging demographic, as advanced age stands as the most significant risk factor for developing the majority of cancer forms, with most instances appearing in individuals over 65 years old. Lutetium-177 Supply facilitates targeted cancer treatments that administer precise radiation to tumor cells while simultaneously reducing harm to healthy tissues, thus enhancing treatment outcomes for neuroendocrine tumors and metastatic prostate cancer, and advancing personalized oncology care worldwide. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization, over 35 million new cancer cases are foreseen by 2050, representing a 77% increase from the approximately 20 million cases in 2022. Consequently, the rising prevalence of cancer is fueling the expansion of the lutetium-177 supply market.
Cardboard Cat Scratcher Market Segments: Where Are The Largest Growth Opportunities?
The lutetium-177 supply market covered in this report is segmented –
1) By Production Method: Reactor Produced Lutetium One Hundred Seventy-Seven; Cyclotron Produced Lutetium One Hundred Seventy-Seven; Carrier Added Lutetium One Hundred Seventy-Seven; Non Carrier Added Lutetium One Hundred Seventy-Seven
2) By Distribution Channel: Direct Supply Agreements; Radiopharmaceutical Distributors; Hospital Procurement Channels; Research Supply Networks
3) By Application: Neuroendocrine Tumor Treatment; Prostate Cancer Treatment; Bone Metastasis Treatment; Clinical Research Applications; Other Applications
4) By End User: Hospitals; Specialty Cancer Clinics; Research Institutes; Radiopharmaceutical Companies; Diagnostic Centers
Subsegments:
1) By Reactor Produced Lutetium One Hundred Seventy-Seven: Direct Neutron Activation Reactor Produced Lutetium One Hundred Seventy-Seven; Indirect Reactor Produced Lutetium One Hundred Seventy-Seven; High Purity Reactor Produced Lutetium One Hundred Seventy-Seven; Medical Grade Reactor Produced Lutetium One Hundred Seventy-Seven
2) By Cyclotron Produced Lutetium One Hundred Seventy-Seven: Proton Irradiation Cyclotron Produced Lutetium One Hundred Seventy-Seven; High Specific Activity Cyclotron Produced Lutetium One Hundred Seventy-Seven; Research Grade Cyclotron Produced Lutetium One Hundred Seventy-Seven; Commercial Scale Cyclotron Produced Lutetium One Hundred Seventy-Seven
3) By Carrier Added Lutetium One Hundred Seventy-Seven: High Activity Carrier Added Lutetium One Hundred Seventy-Seven; Reactor Derived Carrier Added Lutetium One Hundred Seventy-Seven; Clinical Grade Carrier Added Lutetium One Hundred Seventy-Seven; Industrial Use Carrier Added Lutetium One Hundred Seventy-Seven
4) By Non Carrier Added Lutetium One Hundred Seventy-Seven: High Specific Activity Non Carrier Added Lutetium One Hundred Seventy-Seven; Medical Grade Non Carrier Added Lutetium One Hundred Seventy-Seven; Therapeutic Use Non Carrier Added Lutetium One Hundred Seventy-Seven; Research And Diagnostic Non Carrier Added Lutetium One Hundred Seventy-Seven
Development Of Multi-Isotope Production Capabilities In Nuclear Medicine
Major companies operating in the lutetium-177 supply market are focusing on developing advanced initiatives, such as large-scale commercial radioisotope production plaforms to enhance the availability, reliability, and scalability of medical isotopes used in targeted cancer therapies and diagnostic imaging applications. Large-scale commercial radioisotope production platforms are advanced manufacturing systems designed to produce medical isotopes in high volumes through scalable irradiation and purification processes, helping ensure a stable, reliable, and continuous supply of therapeutic and diagnostic isotopes for cancer treatment and nuclear medicine applications. For instance, in January 2025, Nusano Inc., a US-based radioisotope development company, launched commercial isotope operations and announced a lutetium-177 supply agreement with GlyTherix. The initiative supports the production and supply of Lu-177 for targeted radiopharmaceutical therapies and also provides future access to isotopes including actinium-225, zirconium-89, lead-212, and terbium-161. Nusano’s flagship facility in West Valley City, Utah, is designed to simultaneously produce up to 12 different radioisotopes and ultimately support a portfolio of more than 25 isotopes for life sciences applications. The platform enhances isotope supply reliability for clinical trials and commercial therapeutic programs, particularly for oncology-focused radiopharmaceuticals targeting aggressive cancers through precision molecular therapies.
Lutetium-177 Supply Market Key Companies And Competitive Benchmarking
Major companies operating in the lutetium-177 supply market are Novartis AG; Telix Pharmaceuticals Limited; Bayer AG; Cardinal Health Inc.; Siemens Healthineers AG; Curium International Trading B.V.; Eckert & Ziegler SE; NRG PALLAS B.V.; State Atomic Energy Corporation Rosatom; Framatome SAS; BWX Technologies Inc.; National Centre for Nuclear Research Radioisotope Centre POLATOM; Isotopia Molecular Imaging Ltd.; Nusano Inc.; ITM Isotope Technologies Munich SE
Access The Complete Lutetium-177 Supply Market Report:
Lutetium-177 Supply Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the lutetium-177 supply market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lutetium-177 supply market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.